EU Panel Recommends Wegovy for Preventing Cardiac Events, Following FDA Lead

1. EU Panel Recommendation: The European Union's drug regulator is considering expanding the use of Novo Nordisk's weight-loss drug Wegovy to include reducing the risk of strokes and heart attacks, following the FDA's approval for this indication.
2. SELECT Trial Findings: The SELECT trial demonstrated a 20% decrease in heart attacks, strokes, and heart disease-related deaths in obese participants, leading to the label expansion request.
3. FDA Approval: The FDA approved Wegovy for reducing the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and either obesity or overweight.
4. Mechanism of Action: Wegovy contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, which helps in weight loss and reduces cardiovascular risk.
5. Potential Competition: Eli Lilly's weight-loss drug Mjaro, with a similar mechanism of action, may offer similar cardiovascular benefits, potentially competing with Wegovy in the market.